Pharmaceutical Technology

SEPTEMBER 8, 2022

The expert services rendered by them help in improving patient outcomes, minimising costs of the healthcare system, improving medicinal adherence and persistency and saving clinicians’ time. Patient monitoring for safety and efficacy. The post Leading speciality pharmacies in pharma appeared first on Pharmaceutical Technology.

Specialization 45

Specialization Leads Pharma Side effects 45

Pharmaceutical Technology

SEPTEMBER 15, 2022

Packaging plays a vital role in maintaining the quality, safety, user-friendliness and marketability of drugs and other pharmaceutical products. Pharmaceutical Technology has listed some of the leading contract commercial packaging companies, based on its intel, insights and decades-long experience in the sector.

Leads 52

Leads Marketing Pharmaceutical manufacturing Pharmaceutical 52

Pharmaceutical Technology

SEPTEMBER 20, 2022

Pharmaceutical Technology has listed the leading commercial dose non-sterile companies in contract marketing based on its intel, insights, and decades of experience in the sector. Newly emerging technologies have helped in improving the effectiveness and safety of non-sterile commercial dose products.

Leads 52

Leads Marketing Retail Distribution 52

European Pharmaceutical Review

JANUARY 25, 2024

Within the EU, patient information leaflets (PILs) are not merely a regulatory requirement but a cornerstone of patient safety. They are vital to ensuring the safe and effective use of medicines, making them an integral part of healthcare in Europe. percent as EU average with some Member States as high as 25 percent).

Healthcare 84

Healthcare Healthcare Electronics Safety 84

European Pharmaceutical Review

MAY 29, 2023

A neurosteroid drug was one of two medicines recommended for approval at the Committee for Medicinal Products for Human Use (CHMP) ’s May 2023 meeting. This medicinal product has potential to diagnose this cancer in high risk patients in early stages and for patients with suspected recurrence.

Medicine 92

Medicine Marketing Safety Leads 92

Pharmaceutical Technology

SEPTEMBER 20, 2022

Clinical packaging and labelling follow stringently controlled procedures and high-standard quality control measures to assure the safety and functionality of investigational medicinal products, during their storage, distribution, and use.

Leads 40

Leads Marketing Distribution Pharmaceutical 40

European Pharmaceutical Review

SEPTEMBER 20, 2022

The Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have announced that biosimilar medicines authorised in the European Union (EU) can now be interchanged with their reference medicine or an equivalent biosimilar product. New regulatory guidance could lead to UK biosimilar boom.

Medicine 91

Medicine Side effects Safety Doctors 91

European Pharmaceutical Review

MARCH 18, 2024

A Phase III trial has shown that compared oral drug delivery, administering levodopa through an infusion pump led to nearly two hours of day (1.72) of additional time in which the medicine reduced symptoms in Parkinson’s patients. There were 381 Parkinson’s patients enrolled in the trial. and Joan A.

Food and Drug Administration 91

Food and Drug Administration Medicine Physicians Food 91

Pharmaceutical Technology

JUNE 2, 2023

Although health officials from the European Medicines Agency believe portfolio diversification is crucial to hedge against any resurgence of the virus and the emergence of newer variants, the prevention of Covid-19 in the EU is at high risk of being dominated by only one product—at least until the end of 2026.

Leads 52

Leads Safety Distribution Marketing 52

European Pharmaceutical Review

OCTOBER 20, 2022

Apogenix’s lead immunotherapy candidate, asunercept is a fully human fusion protein, consisting of the CD95 receptor and an IgG1 antibody. The Phase II trial investigated efficacy and safety of asunercept in 435 patients with moderate to severe COVID-19 disease.

Patients 101

Patients Safety Medicine Leads 101

Pharmaceutical Technology

SEPTEMBER 14, 2022

Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development. Discover the top API protein and peptide companies in contract marketing.

Leads 52

Leads Marketing Pharmacology Retail 52

European Pharmaceutical Review

OCTOBER 20, 2023

This cytokine drives the type-2 inflammatory loop in the skin, which leads to skin barrier dysfunction, itch, skin thickening and infection. The safety profile of lebrikizumab in ADjoin was found to be consistent with previous lebrikizumab studies in patients with moderate-to-severe atopic dermatitis.

Safety 92

Safety Pharmaceutical Patients Medicine 92

European Pharmaceutical Review

APRIL 17, 2024

Factors supporting expansion of the rapid sterility testing market Concerns around the safety of biological medicinal products is rising and will contribute to expansion of the sterility testing sector in the subsequent years, according to the report. It is expected hold a compound annual growth rate (CAGR) of 8.20

Marketing 85

Marketing Safety Pharmaceutical Medicine 85

European Pharmaceutical Review

DECEMBER 14, 2023

Decisions to remove medicines from market are not taken lightly and are often based upon all evidence available to inform a benefit/risk balance. Over the past few years, we have researched the types of evidence used in regulatory decisions for drug product withdrawals due to safety concerns in Europe.

Safety 113

Safety Medicine Competition Networking 113

European Pharmaceutical Review

DECEMBER 12, 2023

In recent years, nitrosamines have been detected in various medicines, leading to voluntary product recalls from the market. Nitrosamines analysis is, thus, key to ensuring safety and quality in the pharmaceutical industry.

Pharmaceutical manufacturing 59

Pharmaceutical manufacturing Safety Pharmaceutical Manufacturing 59

Pharmaceutical Technology

APRIL 3, 2023

Hyrimoz has been approved for use in all the indications covered by the reference medicine Humira, including plaque psoriasis, rheumatic diseases, ulcerative colitis, Crohn’s disease, uveitis and hidradenitis suppurativa. Its reference medicine, Humira, initially received approval with an adalimumab 50 mg/mL concentration.

Marketing 105

Marketing Food and Drug Administration Medicine Food 105

Healthcare Success

MAY 9, 2022

In this blog post, you’ll learn: Why QR codes have made a comeback, When to use them, And, 8 ways to improve the patient experience and drive leads with QR codes. . Suddenly the safety of contactless, hygienic interactions became a necessity. 8 Ways to Improve the Patient Experience & Drive Leads with QR Codes.

Leads 52

Leads Patients Healthcare Provider Healthcare 52

European Pharmaceutical Review

AUGUST 11, 2023

The European Commission has revoked the conditional marketing authorisation (MA) for Novartis’ sickle cell medicine crizanlizumab in the European Union (EU) and EEA. The decision follows a May recommendation from the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP).

Marketing 86

Marketing Food and Drug Administration Medicine FDA 86

European Pharmaceutical Review

AUGUST 24, 2023

Therefore “This could improve the overall safety and tolerability of risvodetinib.” “… compared to the capsules currently in use in the 201 clinical trial, the smaller tablets may overcome challenges patients have swallowing oral medication as a result of their disease.

Safety 89

Safety Medical Medicine Patients 89

European Pharmaceutical Review

JANUARY 22, 2024

Market growth factors Pharmaceutical extractable and leachable (E&L) testing services The heightened and increasing demand for biopharmaceutical medicines has resulted in greater demand for E&L testing in drug safety , such as when mitigating cross-contamination risks, the report highlighted. percent in 2022.

Marketing 52

Marketing Safety Medicine Pharmaceutical 52

European Pharmaceutical Review

AUGUST 29, 2023

Experts at the European Medicines Agency (EMA) have provided a regulatory perspective on risk factors and mitigation strategies for nitrosamine impurities in human drug products. The paper highlighted an Article 31 referral into medicine safety which began in the EU in September 2019. Cioc et al.

Medicine 90

Medicine Manufacturing Safety Healthcare 90

European Pharmaceutical Review

JANUARY 27, 2023

The UK will be the first country to introduce a tailored framework for the regulation of innovative medicines manufactured at the point where a patient receives care, the Medicines and Healthcare products Regulatory Agency (MHRA) has announced.

Manufacturing 89

Manufacturing Medicine Consulting Engineering 89

European Pharmaceutical Review

FEBRUARY 26, 2024

At its February 2024 meeting, the EMA’s human medicines committee (CHMP) recommended the extension of marketing authorisations for six treatments, and positive opinions for the approval of ten medicines. These products were designated as an orphan medicine during their development.

Medicine 90

Medicine Patients Marketing Pharmaceutical 90

Pharmaceutical Technology

DECEMBER 15, 2022

Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments. By collaborating with world-leading research institutions such as Washington University in St.

Medicine 98

Medicine Safety Sales Leads 98

European Pharmaceutical Review

JANUARY 17, 2023

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for Ximluci ® (ranibizumab), a biosimilar referencing Lucentis®, to help treat a leading cause of blindness globally. First bispecific antibody approved in EU to combat leading causes of vision loss.

Manufacturing 86

Manufacturing Marketing Medicine Safety 86

World of DTC Marketing

MARCH 23, 2022

Accelerated Approval allows for early access to drugs and biologics based on initial evidence of safety and effectiveness, while confirmatory studies required to verify clinical benefits are ongoing. The program was codified into law under the Food and Drug Safety and Innovation Act (FDASIA) in 2012. Do patients care?

Patients 200

Patients FDA Doctors Physicians 200

pharmaphorum

JANUARY 3, 2023

A pharmacologist by training, Rawlins was the founding chairman of health technology assessment (HTA) agency NICE , leading the organisation from its inception in 1999 until 2013, and hired Sir Andrew Dillon to become the organisation’s founding chief executive.

Side effects 52

Side effects Medicine Safety Healthcare 52

European Pharmaceutical Review

OCTOBER 20, 2022

City of Hope , one of the largest cancer research and treatment organisations in the US, announced that the first patient to receive novel cancer medicine AOH1996, is doing well. Its objective is to determine the maximum tolerated dose of the investigational pill, AOH1996, and to evaluate the medicine for preliminary efficacy.

Patients 96

Patients Medicine Safety Medical 96

PM360

OCTOBER 28, 2022

Likewise, it enables them to predict the effect of the compound on the target and the compound’s safety risks. Clinical trials: Evaluating the safety and efficacy of new drugs consumes up to half of the total cost of the drug development process.

Pharma 105

Pharma Food and Drug Administration Government Medicine 105

European Pharmaceutical Review

JANUARY 29, 2024

During 2023, there were five revisions to the European Medicines Agency ’s (EMA’s) Questions and Answers (Q&As) for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products.

Pharmaceutical 98

Pharmaceutical Food and Drug Administration Medicine FDA 98

MedCity News

JANUARY 30, 2024

With the rise of AI technologies, we could see significant advancements in cancer treatment, making it more efficient and potentially leading to a cure. By analyzing vast amounts of data from medical records, laboratory tests and imaging scans, AI algorithms can provide a more precise diagnosis, which can lead to better treatment outcomes.

Side effects 126

Side effects Ethics Medical Patients 126

European Pharmaceutical Review

AUGUST 10, 2023

What Novo Nordisk will gain from the acquisition Through the acquisition agreement, the pharma company Novo Nordisk intends to investigate Inversago Pharma’s lead development asset, a potential first-in-class small molecule CB1 receptor (CB1r) blocker CB1 inverse agonist as a treatment for obesity and obesity-related complications.

Pharma 80

Pharma Safety Leads Medicine 80

European Pharmaceutical Review

MARCH 11, 2024

HIV treatment and prevention are at an inflection point after years of continuously improving the standard of care of once-daily oral medicines. Our industry is on the cusp of the next wave of medicines that will guide the coming decade of HIV care, making HIV a smaller part of people’s lives. 3 But that paradigm is rapidly changing.

Medicine 92

Medicine Pharmacology Healthcare Healthcare 92

Pharmaceutical Technology

APRIL 21, 2023

Moderna CEO Stéphane Bancel said: “Since our inception, we have always strived to be at the forefront of cutting-edge technology, leveraging innovations to deliver the greatest possible impact to people through mRNA medicines. “We Moderna aims to leverage MoLFormer to optimise lipid nanoparticles and mRNA.

Medicine 98

Medicine Networking Safety Leads 98

European Pharmaceutical Review

JUNE 29, 2023

Results from the studies were recently published in the New England Journal of Medicine. LUCENT-1 and LUCENT-2 Phase III clinical trials The Phase III clinical trials assessed the safety and efficacy of mirikizumab compared to placebo in 1,281 adult ulcerative colitis patients with moderate to severe inflammation.

Medicine 88

Medicine Patients Safety Manufacturing 88

pharmaphorum

SEPTEMBER 20, 2022

Findings from the litifilimab trial, undertaken by Northwell Health’s Division of Rheumatology and The Feinstein Institutes for Medical Research, have been published in the New England Journal of Medicine and show promise for those who have been diagnosed with systemic lupus erythematosus (SLE). Sponsored by Biogen Inc., Dr Kevin J.

Medicine 105

Medicine Leads Safety Medical 105

pharmaphorum

NOVEMBER 14, 2022

The EMA’s human medicines committee (CHMP) has recommended IL-4 and IL-13 inhibitor Dupixent (dupilumab) to treat adults with moderate to severe PN, a disease which causes hard lumps to form on the skin that are so itchy they can lead patients to scratch themselves to the point of bleeding or pain.

Sales 91

Sales Medicine Patients Leads 91